R isk stratification of patients with aortic stenosis (AS) is important especially in high-risk asymptomatic patients, patients with atypical symptoms, and those with symptoms but with a high surgical or procedural risk. Current American College of Cardiology/American Heart Association guidelines for indications to proceed with aortic valve replacement (AVR) for AS are the presence of symptoms because of AS, a left ventricular (LV) ejection fraction of <50%, and the need for concomitant valve repair or coronary artery bypass grafting. 1 However, reliance on patient-reported symptoms can be misleading. Patients may knowingly or unknowingly adjust their lifestyles to avoid exacerbating symptoms or may not notify their physicians at the onset of symptoms. It may also be difficult to distinguish whether symptoms are caused by AS when patients have other comorbidities, such as lung disease or deconditioning, the latter being a major concern in elderly patients. Furthermore, the requisite serial followup at 6-to 12-month intervals 1 to ensure that patients are clinically and echocardiographically stable may be difficult for elderly, infirm, or economically disadvantaged patients. Surgical delays because of unrecognized symptoms from AS or infrequent follow-up increase the risk of lethal complications and operative risk. 2 In the past few years, 2 factors have been emerged which may change the current guideline-driven approach to AVR: (1) the advent of transcatheter AVR (TAVR) and (2) the recognition that patients with low-gradient AS also benefit from AVR. 1 Although the procedural risk may be lower in TAVR versus surgical AVR (SAVR), both carry potential complications, including those associated with prosthetic valves. Therefore, optimal timing for the referral to AVR remains important and any development that enhances risk stratification of patients is important for the management of asymptomatic and symptomatic patients with severe AS. 2, 3 As shown in Figure 1 , natriuretic peptides, such as brain natriuretic peptide (BNP) and its precursor N-terminal pro-BNP (NT-proBNP), are released from the myocardium with increased wall stress both from volume and pressure overload, the latter of which occurs in AS. Figure 2 depicts how BNP is cleaved from precursors rendering biologically active BNP and inactive amino-terminal fragment NT-proBNP. 4 NT-proBNP has a 5 to 10 fold longer half-life than BNP. 5 Both biomarkers have become an essential tool for the diagnosis, treatment, and prognostication of congestive heart failure. 6 As established in a large population sample, 7 BNP levels increase with aging, which is why some studies use a BNP ratio (ie, BNP levels adjusted for age-specific normal values). 8 The purpose of this review is to present the data that have emerged during the past 10 years about the usefulness of natriuretic peptides for risk stratification and management of both symptomatic and asymptomatic patients with severe AS.
BNP for the Prediction of Symptom Development in AS
In AS, BNP elevation usually occurs before symptoms develop. There have been several studies, which evaluated the risk of asymptomatic AS patients developing symptoms, having an abnormal stress test, or developing heart failure, all of which would indicate increased mortality risk and therefore need for AVR. In one study, Rajani et al 3 followed 65 asymptomatic patients with an effective aortic orifice area <1.5 cm 2 . Twenty-seven percent of patients developed symptoms with or without exercise stress testing within 1 year. A BNP of >58 pg/mL had a sensitivity of 86% and a specificity of 64% to predict symptomatic AS. This cut-off could help risk stratify asymptomatic patients by prompting exercise testing and closer follow-up at no longer than 6-month intervals in between clinic visits as opposed to 12 months which current guidelines recommend. 1 As shown in Figure 3 , the sensitivity and specificity of different BNP cut-off values for the prediction of symptom onset are clinically meaningful, and therefore, BNP could become a biomarker indication for surgery. 3, [9] [10] [11] [12] However, randomized trials will be necessary to support such a strategy. Table 1 documents the strong relationship between natriuretic peptides and heart failure symptoms in AS. 2, 5, 9, 10, [13] [14] [15] [16] [17] In the largest study, including 373 patients with severe AS, increasing levels of NT-proBNP correlated with higher New York Heart Association class, as well as other markers of increased surgical risk. 14 Bergler-Klein et al 2 confirmed the close correlation of BNP with symptom status in severe AS. BNP <130 pg/mL and plasma NT-proBNP levels <592 pg/ mL were less likely to progress to symptoms and require surgery for the following 6 to 9 months (90% and 88% symptomfree survival, respectively). This important study supports a potential strategy of watchful waiting with assessment of BNP as an integral part of managing asymptomatic patients. 10 Similar data exist for the usefulness of serial NT-proBNP measurements, a strategy that we often use in our practice. 18 The Cohorte Française de Retrecissement Aortique du Sujet Agé and Genetique du Retrecissement Aortique (COFRASA-GENERAC) study showed by univariate analysis, however not by multivariate analysis, that NT-proBNP was associated with AS-related complications, including new symptom onset. This suggests that BNP can be a useful tool to stratify highrisk asymptomatic patients but should be used along with other clinical data. 19 
BNP and AS Severity
NT-proBNP levels correlate to some extent with mean and peak transaortic valvular gradient and inversely correlate with aortic valve area. 20 Eight of 10 studies found that smaller aortic valve area is associated with higher BNP/NT-proBNP levels. 9, 10, 13, 15, 19, [21] [22] [23] Ben-Dor et al 24 found that greater levels of BNP also correlate significantly with higher surgical risk and atrial fibrillation, lower ejection fraction and higher pulmonary, and LV pressures, but they did not find that BNP correlated with aortic valve area, which is in contrast to several studies that found BNP levels are linked to AS severity. 17, 20, 25 One possible explanation for this negative finding was a relatively high prevalence of chronic kidney disease (45%) and LV dysfunction, both of which can confound measurement of BNP. With regard to mean aortic valve gradient, 5 of 7 studies listed in Table 2 showed that higher BNP or NT-proBNP levels are associated with a greater mean aortic valve gradient. 5, 10, 13, 17, 19, 21 Table 2 lists studies that correlated natriuretic peptides with AS severity and cardiac remodeling. 5, 9, 10, [13] [14] [15] 17, 19, [21] [22] [23] [24] 26, 27 
BNP and LV Hypertrophy
As shown in Figure 4A , multiple studies demonstrated a correlation between natriuretic peptides and LV mass by echocardiography. 9, 13, 15, 16, 21, 22, [25] [26] [27] [28] [29] LV hypertrophy (LVH) develops initially as adaptive response to pressure overload in patients with AS. Increase BNP gene expression leading to greater levels of natriuretic peptides may reflect more pronounced hypertrophic myocardial growth from elevated LV wall stress caused by increased afterload. 16, 23, 28, 29 Wu et al 30 found that NT-proBNP levels are 3.5× higher in mild to moderate AS and 6× higher in severe AS compared with the control group without valvular disease. This relationship correlated with a 1.7× higher LV mass index (LVMI) in mild to moderate AS and 2.1× higher LVMI in severe AS compared with control. Others have confirmed this relationship between natriuretic peptide levels and LVMI in patients with chronic severe AS. 5, 13, 15, 16, 20, 21, 23, 26, 27, 29, 31, 32 Eccentric LVH-which may be indicative of a later stage of LV decompensation or mixed regurgitant/stenotic lesions-is associated with higher BNP levels than concentric LVH. 16 The same correlation between BNP levels and LVMI was found in a study of patients undergoing transapical TAVR. Importantly, a higher baseline NT-proBNP independently predicted greater regression of LVMI and improvement of functional capacity 2 months after TAVR. Therefore, natriuretic peptides may be a good indicator of both positive remodeling (LVH) before AVR and negative remodeling (regression of LVH) after AVR. 33 
BNP and LV Function in AS
LV pressure overload caused by severe AS induces an adaptive process with the intent to maintain myocardial wall stress. However, this adaptive process becomes maladaptive when physiological limits are crossed and a stage of LV decompensation sets in. As shown in Table 2 , natriuretic peptides may be useful to detect this maladaptive transition because elevated levels are associated with increased LV and left atrial dimensions, decreased LV function, and increased systolic pulmonary artery pressure. 2, 13, 16, 21, 27, 29 Figure 4B demonstrates that in most studies, there is an inverse correlation between higher levels of natriuretic peptides and ejection fraction in patients with AS. 2, 9, 13, 15, 16, 21, 22, 27, 34 One large prospective study of 289 patients referred for TAVR found that higher levels of BNP were independently associated with lower ejection fraction (35.5% versus 55.4%). 24 Iwahashi et al 15 and several other studies confirmed this association. 2, 9, 13, 16, 21, 22, 27, 34 In conservatively treated patients with AS, a reduced LV ejection fraction is associated with increased risk, suggesting that at this advanced stage, AVR, although high-risk, is urgently indicated. However, TAVR may be safer than SAVR in such patients. 9
BNP and Mortality
Multiple studies listed in Table 3 demonstrate a strong relationship between natriuretic peptides and increased mortality in patients with AS before AVR. 5, 8, 10, [12] [13] [14] [15] 33, [35] [36] [37] [38] Lim et al 10 found that BNP was a strong independent predictor of cardiovascular death regardless whether patients were symptomatic or asymptomatic. In a prospective study by Katz et al, 5 patients with higher plasma BNP (>135 pg/mL) and NT-proBNP (>1150 pg/mL) levels at baseline had a greater risk of long-term mortality for ≤6 years. Elhmidi et al 14 extended these findings to NT-proBNP levels, which also predicted 1-year mortality. Nessmith et al 12 found a substantial 1-year mortality rate without surgery of 60% for BNP >819 pg/ mL, whereas there was no mortality in patients with BNP <100 pg/mL in the same time frame. This and other studies listed in this section clearly show that BNP has independent prognostic values beyond symptoms and LV function on echocardiogram. In the True Or Pseudo Severe Aortic Stenosis (TOPAS) study, the cumulative 1-year mortality of patients with low-flow, low-gradient AS with BNP ≥550 pg/ mL was 53% compared with only 3% in patients with BNP <550 pg/mL. 35 Antonini-Canterin et al 13 reported that 65% of patients with AS with BNP ≥254 pg/mL compared with 7% of patients with BNP<254 pg/mL had an adverse outcome, including cardiac mortality, urgent AVR, or decompensated heart failure. Clavel et al 8 used the BNP ratio (age-and sexadjusted BNP value) to assess survival in patients with AS.
Eight-year survival was 62±3% with a normal BNP, 44±3% with a BNP ratio of 1 or 2, 25±4% with a BNP ratio of 2 or 3, and only 15±2% with a BNP ratio of ≥3. This strong correlation of BNP ratio to survival also held up in asymptomatic patients with normal ejection fraction. In contrast, Ben-Dor et al 24 did not find an association of BNP with mortality in patients with AS.
BNP and Postoperative Mortality
As shown in Table 3 , Pedrazzini et al 37 demonstrated that BNP predicted postoperative all-cause mortality more accurately than the logistic EuroSCORE (logEs), a widely used risk score for cardiac surgery, with an optimal discriminatory cutoff of >312 pg/mL. Iwahashi et al 15 identified the same BNP cut-off value in their study. In contrast, Clavel et al 8 found that the increased mortality associated with a greater BNP ratio did not translate in a greater mortality after AVR. AVR Table 1 AS indicates aortic stenosis; AVA, aortic valve area; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; SAVR, surgical aortic valve replacement; and TAVR, transcatheter aortic valve replacement.
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Table 2. Correlation of Natriuretic Biomarkers With AS Severity and Other Echo Parameters
Parameter
Author reduced mortality similarly in patients with a low or a high BNP ratio. The usefulness of BNP to predict mortality after TAVR has not been evaluated in adequately powered studies and thus remains controversial. However, Kefer et al 36 performed a survival analysis on high-risk patients with severe AS, who underwent TAVR. A baseline BNP level of >428 pg/ mL was associated with a higher 30-day mortality, as was a BNP increase of >170 pg/mL 24 hours after TAVR. These data suggest that postprocedure BNP levels could also be used to influence postoperative care and follow-up. In another study, also limited by a small sample size of 31 patients undergoing TAVR, NT-proBNP was associated with LV mass regression after TAVR but not with 2-month mortality after TAVR. However, with only 3 deaths occurring after first month and 5 deaths after second month, a false-negative result because of lack of statistical power is likely. 30
Significance of Postoperative BNP Levels
Immediately after SAVR, natriuretic peptides increase because of cardiopulmonary bypass, blood pressure fluctuations during anesthesia, and the large fluid shifts that occur during cardiac surgery. Peak levels of NT-proBNP are usually seen 24 hours after surgery 20, 27 and decrease thereafter. 24 This late decrease in natriuretic peptide levels correlates with reverse myocardial remodeling, specifically a reduction in LV mass and LV dimensions and improvement in LV systolic function. 2, 23, 25, 26, 31, 39 A similar reduction in natriuretic peptides occurs after TAVR and balloon aortic valvuloplasty. 14, 24, 40 Gotzmann et al 41 showed that 30 days after TAVR, there is a significant decrease of BNP (from 725±837 to 423±320), which was accompanied by decreased myocardial wall stress, improvement in quality of life measures, and 6-minute walk distance. Considering these data, which are summarized in the Table I in the Data Supplement, natriuretic peptides seem to have prognostic values not only before but also after AVR.
Practical Considerations
As measurement of natriuretic peptides in asymptomatic patients with valvular heart disease is currently not supported by recent guidelines, 1 lack of reimbursement could be prohibitive in some cases. In our opinion, measurement of natriuretic peptides is useful and therefore should be reimbursed. In addition, noncardiac causes for increased (ie, chronic kidney disease) or decreased (ie, obesity) levels of natriuretic peptides have to be considered. Following natriuretic peptide trends has been useful in our experience because relative changes may be more meaningful than absolute values in the assessment of patients with asymptomatic severe AS.
Natriuretic peptides also have a potential role in risk stratifying patients with other valvular heart diseases, such as aortic regurgitation and mitral regurgitation. Although the discussion of this topic is beyond the scope of this review, natriuretic peptides correlate with the severity of regurgitation, 25, 42 LV remodeling and dysfunction, [43] [44] [45] symptomatic status, 46, 47 and mortality 45, 48 in mitral regurgitation and aortic regurgitation.
Comment
Optimal timing for the referral of asymptomatic patients with severe valvular AS remains a challenge. A decade of investigations studying the usefulness of natriuretic peptides in the management of AS establish a solid evidence base for their use in the management of patients with AS. Natriuretic peptides correlate with the severity of AS, the extent of myocardial remodeling, the transition between asymptomatic and symptomatic AS and identify high-risk groups in whom SAVR is associated with an increased risk. Importantly, natriuretic peptides augment our understanding of the hemodynamic burden of AS in an individual patient. Although watchful waiting has worked well in light of the risks and discomforts of SAVR, with the advent of lower-risk TAVR, the threshold for AS treatment may be lowered once results of randomized TAVR trials in lower risk populations become available. Furthermore, once long-term durability of TAVR has been established and adverse events from TAVR, such as stroke, can be further reduced, it will likely become unacceptable to allow progressive remodeling from pressure overload to occur because it implies a worse prognosis. We think that there is compelling evidence to use BNP to risk stratify patients for TAVR or SAVR. Future risk models should include BNP levels. 49, 50 A randomized trial, comparing TAVR and SAVR versus conservative treatment in patients with asymptomatic AS but elevated natriuretic peptides to a level that reflects increased morbidity and mortality, is warranted. As shown in A, the correlation between brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) is stronger for left ventricular mass index than for left ventricular ejection fraction (B) and seems to be weaker in patients with normal ejection fraction. Baseline BNP ≤312 pg/mL linked with greater event-free survival post SAVR compared with BNP >312 pg/mL … AS indicates aortic stenosis; AVA, aortic valve area; AVR, aortic valve replacement; BNP, brain natriuretic peptide; BSA, body surface area; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; SAVR, surgical aortic valve replacement; and TAVR, transcatheter aortic valve replacement.
*BNP ratio: defined as the BNP level divided by age-adjusted maximal normal BNP level.
